Anixa Biosciences, Inc.ANIXNASDAQ
Loading
Operating Expenses Over TimeStable
Percentile Rank53
3Y CAGR-0.1%
5Y CAGR-3.6%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-0.1%/yr
vs -2.0%/yr prior
5Y CAGR
-3.6%/yr
Recent acceleration
Acceleration
+1.9pp
Accelerating
Percentile
P53
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
2 yr
Consecutive declineStable
| Period | Value | YoY Change |
|---|---|---|
| TTM | $11.02M | -5.5% |
| 2025 | $11.66M | -15.7% |
| 2024 | $13.83M | +25.1% |
| 2023 | $11.06M | -20.3% |
| 2022 | $13.88M | +4.6% |
| 2021 | $13.26M | +34.1% |
| 2020 | $9.89M | -17.4% |
| 2019 | $11.97M | -12.8% |
| 2018 | $13.72M | +116.7% |
| 2017 | $6.33M | - |